Research Article
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
Table 3
Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and macular volume (MV) over the first year of follow-up.
| | Baseline | Month 3 | Month 6 | Month 9 | Month 12 |
| | Number of eyes | | | | | | | BCVA (ETDRS letters ± SD) | 56.5 ± 11.9 | 62.9 ± 12.4 | 62.6 ± 13.0 | 63.0 ± 12.2 | 63.4 ± 13.8 | | CRT (μm ± SD) | 470 ± 134.5 | 322 ± 97.8 | 344.7 ± 122.8 | 350.5 ± 99 | 361.9 ± 124.8 | | MV (mm3 ± SD) | 13.2 ± 2.4 | 11.2 ± 1.5 | 11.4 ± 1.7 | 11.6 ± 1.7 | 11.6 ± 1.6 | | BCVA > 70 letters | 5 (6.9%) | 22 (36.6%) | 18 (31%) | 16 (30.7%) | 14 (31.1%) | | | | 0–3 months | 0–6 months | 0–9 months | 0–12 months | | Number of eyes | | | | | | | BCVA gain (ETDRS letters ± SD) | | +6.4 ± 7.3 | +6.1 ± 16.7 | +6.5 ± 8.5 | +6.9 ± 10.2 | | Change in CRT (μm ± SD) | | −148 ± 177 | −125.3 ± 177 | −119.5 ± 143 | −108.1 ± 176 | | Change in MV (mm3 ± SD) | | −2 ± 1.6 | −1.8 ± 1.8 | −1.7 ± 1.4 | −1.6 ± 1.6 | | Gain ≥ 10 letters | | 22 (30.5%) | 19 (26.3%) | 18 (25%) | 17 (37.8%) | | Gain ≥ 15 letters | | 9 (12.5%) | 11 (15.2%) | 5 (6.9%) | 10 (22.2%) | | Loss ≥ 10 letters | | 1 (1.3%) | 6 (8.3%) | 2 (2.7%) | 3 (4.1%) | | Loss ≥ 15 letters | | 0 | 3 (4.1%) | 0 | 2 (2.7%) |
|
|
|
